Updated Neoadjuvant Treatment Landscape for Early Triple Negative Breast Cancer: Immunotherapy, Potential Predictive Biomarkers, and Novel Agents

SIMPLE SUMMARY: In recent years, several agents have been tested in randomized clinical trials in addition to anthracycline and taxane-based neoadjuvant chemotherapy (NACT) in early-stage triple-negative breast cancer (TNBC) to improve pathological complete response rate and, ultimately, survival ou...

Descripción completa

Detalles Bibliográficos
Autores principales: Garufi, Giovanna, Carbognin, Luisa, Schettini, Francesco, Seguí, Elia, Di Leone, Alba, Franco, Antonio, Paris, Ida, Scambia, Giovanni, Tortora, Giampaolo, Fabi, Alessandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454536/
https://www.ncbi.nlm.nih.gov/pubmed/36077601
http://dx.doi.org/10.3390/cancers14174064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454536/
https://www.ncbi.nlm.nih.gov/pubmed/36077601
http://dx.doi.org/10.3390/cancers14174064

Ejemplares similares